Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 74Neoplasm Metastasis 11Uveal Melanoma 7Skin Neoplasms 6Neoplasms 5Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Oligodendroglioma 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced Melanoma 1

Interventions

olaparib 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma Neoplasms × Dacarbazine × Dermatologic × Clear all
NCT00516802 2009-05-15

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

AstraZeneca

Phase 1 Completed
40 enrolled
Dermatologic

Melanoma Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡